Evolocumab and Alirocumab are presently the only two fully human PCSK9-targeting mAbs approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the clinical treatment of hypercholesterolemia thanks to their potency, tolerability, and low immunogenicity. Here, PCSK9 is linked to Hypercholesterolemia.